Sections
1. Investment Snapshot
2. Price Chart
3. Thesis
4. Valuation & Price Target
5. Business & Product Moat
6. People & Governance
7. Risk Register
Discussion
Investment Snapshot
Price Chart
Thesis
Valuation & Price Target
Business & Product Moat
People & Governance
Risk Register
Discussion
Odyssey Therapeutics, Inc.
Investment Snapshot
Symbol
ODTX
IPO Date (Actual)
2026-05-08
Offer Range
$18.00
Shares Offered
15.5M
Total Shares Post-IPO
62.7M
Market Cap
—
Target Price
$00.00Implied Upside vs Midpoint
$00.00Use of Proceeds
Fund operations and R&D (advance OD‑001 and OD‑002), fund clinical trials and IND/CTA‑enabling work, support CMC/manufacturing and regulatory activities, build commercial/development capabilities, and working capital. S‑1 states expected proceeds plus existing cash are projected to fund operations into H2 2028.
Price Chart
Historic Price Chart - ODTX
Thesis
Odyssey Therapeutics (ODTX) is a Boston‑area, science‑driven biopharmaceutical company focused on small‑molecule and protein therapeutics targeting innate immune signaling and upstream immune nodes for immune‑mediated and interferon‑mediated diseases. Its discovery platform combines AI ML, proteomics and traditional discovery tools. Lead assets: OD‑001 (oral RIPK2 scaffolding inhibitor; completed Phase 2a proof‑of‑concept in ulcerative colitis) and OD‑002 (oral SLC15A4 inhibitor; in IND‑enabling studies). Business model centers on internal discovery clinical development with near‑term non‑recurring collaboration license revenue and longer‑term commercialization or partner licensing strategies. Primary funding sources are venture financings, collaborations and proceeds from the proposed IPO (S‑1/S‑1A). Financially, Odyssey reported minimal product revenue ($2.976M in 2025), large operating losses (net loss $148.647M in 2025), cash of $216.6M (12/31/2025), an accumulated deficit of ~$568.1M, and expects IPO proceeds + cash to fund operations into H2 2028 per the S‑1.
Valuation & Price Target
████████████████████
Business & Product Moat
████████████████████
Company Description (Source)
Odyssey is a clinical-stage biopharmaceutical company led by a team and board of
drug hunters seeking to transform the standard of care for patients suffering
from autoimmune and inflammatory diseases. We believe our deep understanding of
immunobiology, coupled with leading expertise in medicinal and computational
chemistry, protein biochemistry, structural biology, genetics, and pharmacology,
allows us to identify and drug key signaling nodes that drive disease. We have
prioritized targets where we believe the underlying disease biology is
understood through genetic, clinical, or translational evidence.
Our most advanced programs include OD-001, an oral small-molecule scaffolding
inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an
oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4.
OD-001 has achieved proof-of-concept in a phase 2a trial for the treatment of
ulcerative colitis, or UC, one of the two main types of inflammatory bowel
disease, or IBD, and OD-002 is currently in IND-enabling studies. These programs
have the potential to yield treatments for inflammatory and autoimmune diseases
that have large, addressable patient populations globally and a lack of
effective treatments, including IBD, systemic lupus erythematosus, or SLE, and
other disorders characterized either by the chronic overactivation of the type I
interferon pathway, referred to as interferonopathies, or by pathogenic
autoreactive B cells. In addition to our most advanced programs, we have a
portfolio of wholly owned preclinical programs that include, but are not limited
to, a regulatory T cell, or Treg, -specific tumor necrosis factor receptor 2, or
TNFR2, agonist, a bispecific antagonist of thymic stromal lymphopoietin, or
TSLP, and interleukin-33, or IL-33, and an interleukin-1 receptor-associated
kinase 4, or IRAK4, scaffolding inhibitor. We also have an interferon regulatory
factor 5, or IRF5, inhibitor in preclinical development which we are
collaborating on with Terray Therapeutics, Inc., or Terray.
---
We were incorporated in Delaware in April 2021. Our principal executive offices
are located at 51 Sleeper Street, Suite 800, Boston, Massachusetts 02210, and
our telephone number is (617) 865-9628. Our website address is
https://odysseytx.com/.
Competitor Set
████████████████████People & Governance
Gary D. Glick, Ph.D.
Founder, President & Chief Executive Officer
Strengths
+
Serial biotech founder and drug hunter with prior leadership involvement at companies cited in the S‑1 (examples: IFM, Lycera, Scorpion). Holds a Ph.D.; S‑1 emphasizes domain expertise in innate immunology and small‑molecule discovery and experience advancing programs to IND clinical stages. Appears to have significant scientific credibility and program leadership experience, which is highly relevant for a science‑driven early mid‑stage biotech. Negative / red flags: S‑1 and the accompanying searches did not disclose any litigation, regulatory enforcement, criminal convictions, or SEC actions involving Dr. Glick. The S‑1 does, however, explicitly identify company dependence on key executives (including the CEO) as a risk — i.e., operational concentration risk. No other adverse findings were presented in the materials reviewed.Jeffrey M. Leiden, M.D., Ph.D.
Chair of the Board
Strengths
+
Former President CEO Chair of Vertex Pharmaceuticals with a proven record leading a major, successful biotech; extensive drug‑development, commercialization, corporate governance and capital markets experience. MD PhD credentials and deep industry stature increase board and investor credibility. Negative / red flags: No material adverse legal or regulatory issues were disclosed in the S‑1 or in the ancillary search results provided. As a senior industry executive, potential conflicts of interest are always possible in board roles, but none were disclosed in the S‑1 excerpts reviewed.Shelley Chu, M.D., Ph.D.
Board Member / Partner, Lightspeed Venture Partners
Strengths
+
Venture investor with biotech board experience; brings investor perspective, fundraising and strategic connections to growth capital and partnerships. Likely brings portfolio company operational oversight and commercialization guidance. Negative / red flags: No litigation, enforcement, or other adverse disclosures were found in the S‑1 excerpts reviewed. As a VC partner, potential incentive alignment differences (shorter fund cycles, portfolio priorities) are a generic governance consideration but no specific red flags were identified.Paulina Hill, Ph.D.
Board Member / Partner, Sanofi Ventures
Strengths
+
Venture investor at a strategic pharma VC arm (Sanofi Ventures), likely brings deal partnering expertise and pharma commercialization perspective. Negative / red flags: No legal regulatory issues or other adverse items were disclosed in the S‑1/search results reviewed.Nan Li
Board Member / Co‑founder & Managing Partner, Dimension Capital
Strengths
+
Venture fund founder partner experience—useful for capital strategy, fundraising and industry networks. Negative / red flags: No material adverse disclosures surfaced in the S‑1 excerpts provided.Carolyn Ng, Ph.D.
Board Member / Business Unit Partner, TPG Global (life sciences investor)
Strengths
+
Life‑sciences investment experience at a large private equity venture firm; brings expertise in commercial scaling, corporate governance and capital markets. Negative / red flags: No adverse items or enforcement actions were disclosed in the S‑1 excerpts reviewed.Ian F. Smith
Board Member / Senior biotech executive
Strengths
+
Senior biotech executive with >30 years of finance and operating experience, including former roles at Vertex; public company CEO chair experience provides governance and commercialization expertise. Negative / red flags: No material adverse or regulatory disclosures were identified in the S‑1 excerpts reviewed. The general S‑1 risk that the company depends on attracting and retaining senior management is applicable.Valerie Odegard, Ph.D.
Board Member / CEO of Dovetail Therapeutics
Strengths
+
Current CEO of a clinical‑stage company; experience in drug development in autoimmune disease oncology, operational leadership and commercialization planning. Negative / red flags: No adverse legal regulatory issues were identified in the S‑1 excerpts provided.Ksenija Pavletic
Board Member / General Partner, Jeito Capital
Strengths
+
Investment operational experience in pharma biotech providing commercial and operational perspective. Negative / red flags: No adverse disclosures surfaced in the S‑1 excerpts reviewed.Nia Tatsis, Ph.D.
Board Member / EVP, Chief Regulatory & Quality Officer at Vertex
Strengths
+
Regulatory leadership at a major biotech (Vertex) gives relevant regulatory strategy capabilities for a clinical‑stage company. Negative / red flags: No material adverse findings were disclosed in the S‑1/search results provided.Timothy P. Walbert
Board Member / Former Chairman, President & CEO of Horizon Therapeutics
Strengths
+
Commercial leadership and experience scaling specialty immunology rare disease products; familiarity with payer dynamics and commercialization execution. Negative / red flags: No adverse or enforcement actions were disclosed in the S‑1 excerpts reviewed.Risk Register
High cash burn and large accumulated deficit (accumulated deficit ~$568.1M; net loss $148.647M in 2025) with ongoing financing and dilution risk.
Program concentration and clinical risk: company success depends on a small number of programs (OD‑001, OD‑002) with binary clinical outcomes.
Competitive/commercial risk: crowded immunology markets with established biologics and large‑pharma competitors; need for differentiation, payer acceptance and partnerships to commercialize.